ImmunoGen Gets Centocor Licensing Pact
3610
ImmunoGen Inc. said Tuesday it licensed certain rights to develop cancer-fighting drugs using its cell-killing agents to Johnson &amp; Johnson&#39;s Centocor unit.
551343
Years of clinical trials have yielded promising results for a vaccine that would protect women from a virus that causes cervical cancer.
660314
Scientists say initial studies show promising results for a vaccine which could combat a common type of bacteria.
459866
The Northern California biotechnology company VaxGen yesterday received an $877.5 million contract to provide the federal government with a new anthrax vaccine.
729447
U.S. antitrust authorities on Wednesday approved AstraZeneca Plc's  plan to buy biotechnology company MedImmune Inc.  for more than $15 billion.
408715
The European Commission has proposed a licensing system that would make it easier for European generic drug makers to provide treatments against killer diseases such as AIDS, malaria and tuberculosis to developing countries, it said.
681404
U.S. antitrust authorities on  Wednesday approved AstraZeneca Plc&#39;s  plan to buy  biotechnology company MedImmune Inc.  for more than $15  billion.
281494
The US government announced Thursday that it has awarded an $877.5 million contract to a private company to manufacture and deliver 75 million doses of a new vaccine for inhalation anthrax.
755950
The drugmakers' alliance will benefit both the companies and HIV patients.
35589
The Food and Drug Administration has signed off on the safety of a portion of five (m) million doses that are available from plants in Canada and Germany.
355967
OXiGENE reaches a deal with FDA on its lead compound.
392549
A molecule which may protect against food allergy has been identified.
474237
VaxGen, which shifted its focus to bioterrorism treatments after failures in HIV research, has won an $877 million contract to supply the United States government with anthrax vaccine.
612692
MedImmune Inc. will pay a New Jersey biotech company $15 million to collaborate with it on potential new treatments for autoimmune diseases, starting with lupus. - The Washington Post
536828
The US government has awarded VaxGen a contract to supply 75 million doses of anthrax vaccine for civilian defense. The contract is valued at $877.
476649
A genetically engineered antibody that blocks an immune system molecule has produced promising results in its first use against Crohn&#39;s disease, researchers report.
108565
Danish biotech Genmab A/S on Tuesday signed a deal worth up to $2.1 billion with pharmaceutical company GlaxoSmithKline PLC for the global commercialization of a leukemia treatment.